| Emitents | Grindeks, AS (5299006DWR32NKWM1O86) |
| Veids | Būtiski notikumi |
| Valoda | EN |
| Statuss | Publicēts |
| Versija | |
| Datums | 2011-06-16 11:44:53 |
| Versijas komentārs | |
| Teksts |
Today on 16 June in Riga, 53 Krustils Street, JSC
“Grindeks” has unveiled UDCA
active pharmaceutical ingredient’s
manufacturing unit, which is one of the most significant
investment projects of “Grindeks”. Manufacturing
unit’s construction was started in 2009, after a
multi-stage, long-term cooperation agreement on regular UDCA supply
was concluded with the German pharmaceutical company “Marenis
Pharma”. 6.34 million lats were
invested in the construction of the
new manufacturing unit, out of which 2.8 million
lats was the co-financing by the European Regional Development Fund
(ERDF).
Chairman of the Council of “Grindeks”
Kirovs Lipmans: “Research, development, manufacture and sale of
active pharmaceutical ingredients is one of the business directions
of “Grindeks”, which in recent years, we have purposefully
developed. Investment of 6.34 million lats in the new manufacturing
unit is an important contribution not only to the company's
development, but also to the economy of Latvia. I believe and I see
that the national uplift of Latvia can be achieved directly by
industrial manufacturing and exports. The new manufacturing unit is
a clear sign that the Latvian companies are competitive in the
international arena.”
Chairman of the Board of “Grindeks” Janis Romanovskis:
“Sustainable future of “Grindeks” is most closely related to the
shareholders' interest to invest in the company – to believe in
the idea, and to dare to move towards the objective. Project of
this magnitude is both a serious challenge, and international
recognition, therefore, I wish to express my gratitude to our
shareholders for their willingness to take risk; to the German
cooperation partner “Marenis Pharma” for the confidence; and to
congratulate the team of “Grindeks”, which has once again
demonstrated its professional competence!”
In the manufacturing unit`s opening ceremony, the
Chairman of the Council of “Grindeks” Kirovs Lipmans
has stated that the cooperation between “Grindeks” and the state
institutions of Latvia is becoming more and more successful and at
the same time he has invited state officials to support local
manufacturers.
In the opening ceremony of UDCA
manufacturing unit of “Grindeks” has taken part the Prime Minister
of the Republic of Latvia Valdis Dombrovskis: “Over the past few
years, we have seen that exactly exporting enterprises have helped
to overcome economic difficulties and restore growth. Now, when
Latvia has exceeded pre-crisis export volumes, it is very important
to be able to find new products and niches, new markets and
directions for further export growth. The new manufacturing unit of
“Grindeks” is a step in the right direction; and by attracting the
co-financing by the EU funding of
2.8million lats, the company will manage
to break into new markets and significantly
enhance the export
potential.”
Product development and manufacturing process of UDCA is
complex and time consuming. This is related to refining, hydration,
replacement, crystallisation and other chemical transformation.
Manufacturing processes in the new manufacturing unit are organized
according to the ISO Quality Standard
requirements that in general guarantee safety and
quality of the produced active pharmaceutical
ingredient. In the new plant,
a modern automatic management system is installed, which controls
the microclimate in the premises and the work of engineering
systems, as well as regulates other processes of production and
significantly saves energy. In its turn, convenient, safe,
efficient and environmentally friendly production is provided by
modern and powerful technological devices. UDCA manufacturing
unit`s total area is 2300 square meters. In the new site, 35 new
job positions are created.
The world market of UDCA active pharmaceutical
ingredient is gradually increasing and now accounts for about 400t
a year. In the world, there are five manufacturers of this active
substance. In 2014 “Grindeks” plans to capture
about 15% of UDCA active pharmaceutical ingredient’s world
market.“Grindeks” has
defined vertically integrated solutions as a strategic priority –
to develop and manufacture active pharmaceutical ingredients by its
own resources, from which then produce and sell the finished
product. The next development step in the project of UDCA is the
final dosage form development and implementation during the next
two years.
On
“Grindeks”
“Grindeks” is the leading pharmaceutical company in the
Baltic States. Its main fields of action are: research,
development, manufacturing and sale of original products, generics
and active pharmaceutical ingredients. “Grindeks” specializes in
the heart and cardiovascular, CNS and anti-cancer medication
therapeutic groups.
The Group consists of four subsidiary companies in
Latvia, Estonia and Russia, as well representative offices in ten
countries. Products of the company are exported to 50 countries and
its export comprises more than 95% of the total turnover. The main
markets are: Russia and other CIS countries, the Baltic
States, Germany and the
Netherlands. JSC “Grindeks” shares are listed in the
Official List of “NASDAQ
OMXRiga”.
Further information on the company –
www.grindeks.lv
Further information:
Laila Klavina
Head of the Communications Department
JSC “Grindeks”
Phones: (+371) 67083370, (+371)
29256012
Fax: (+371) 67083505
E-mail:
laila.klavina@grindeks.lv
Project “Creation of Ursodeoxycholic Acid manufacturing
unitwith the necessary
infrastructure” is co-funded by
the European Regional Development
Fund
|
| Pielikumi |